Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 101–200 of 1,002
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Qu, X., Tang, Y., & Hua, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00563 · Cited by 301
“Delivering cancer stem cell therapies – a role for nanomedicines? Eur J Cancer (2006) 42(9):1309–15.”
BackgroundInfluentialCancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
Interferon Gamma in Successful Pregnancies1
Murphy, S. P., Tayade, C., Ashkar, A. A., Hatta, K., Zhang, J., & Croy, B. A. (2009) · Biology of Reproduction · doi:10.1095/biolreprod.108.073353 · Cited by 303
“Disruption of the JAK/STAT pathway is also an important immunoevasion mechanism used by some tumors [7].”
BackgroundJiang, D.-K., Sun, J., Cao, G., Liu, Y., Lin, D., Gao, Y.-Z., Ren, W.-H., Long, X.-D., Zhang, H., Ma, X.-P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2483 · Cited by 309
The intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
Accelerated tumor growth in mice deficient in DNAM-1 receptor
Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 290
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Shi, L., Pan, H., Liu, Z., Xie, J., & Han, W. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.44 · Cited by 292
De Palma, M., Mazzieri, R., Politi, L. S., Pucci, F., Zonari, E., Sitia, G., Mazzoleni, S., Moi, D., Venneri, M. A., Indraccolo, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.004 · Cited by 301
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity
Schadt, L., Sparano, C., Schweiger, N. A., Silina, K., Cecconi, V., Lucchiari, G., Yagita, H., Guggisberg, E., Saba, S., Nascakova, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.065 · Cited by 298
Heikkilä, K., Harris, R., Lowe, G., Rumley, A., Yarnell, J., Gallacher, J., Ben-Shlomo, Y., Ebrahim, S., & Lawlor, D. A. (2009) · Cancer Causes & Control · doi:10.1007/s10552-008-9212-z · Cited by 290
“system can raise an inflammatory response against developing cancer cells [68, 69 ].”
BackgroundInterferon-γ links ultraviolet radiation to melanomagenesis in mice
Zaidi, M. R., Davis, S., Noonan, F. P., Graff-Cherry, C., Hawley, T. S., Walker, R. L., Feigenbaum, L., Fuchs, E., Lyakh, L., Young, H. A., et al. (2011) · Nature · doi:10.1038/nature09666 · Cited by 293
Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Dardalhon, V., Anderson, A. C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903275 · Cited by 278
Anti‐tumour strategies aiming to target tumour‐associated macrophages
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2013) · Immunology · doi:10.1111/imm.12023 · Cited by 278
Paget, C., Mallevaey, T., Speak, A. O., Torres, D., Fontaine, J., Sheehan, K. C. F., Capron, M., Ryffel, B., Faveeuw, C., Leite de Moraes, M., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.017 · Cited by 276
“Thus, to our best knowledge, our report is the first that shows that type I IFN, a key cytokine implicated in antiviral defense and tumor immunity ( Dunn et al., 2006; Stetson and Medzhitov, 2006), cooperates with self Ag(s) to promote iNKT cell cytokine release.”
BackgroundDNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.006 · Cited by 268
PTSD is associated with an excess of inflammatory immune activities
Gill, J. M., Saligan, L., Woods, S., & Page, G. (2009) · Perspectives in Psychiatric Care · doi:10.1111/j.1744-6163.2009.00229.x · Cited by 271
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches
Pandya, P. H., Murray, M. E., Pollok, K. E., & Renbarger, J. L. (2016) · Journal of Immunology Research · doi:10.1155/2016/4273943 · Cited by 259
“Though the innate immunity plays a critical part in regulating cancer pathogenesis, another equally important aspect in cancer biology is the role of adaptive immunity [3, 40].”
InfluentialZhang, P., Su, D.-M., Liang, M., & Fu, J. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.08.013 · Cited by 263
NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268
“Type I IFN enhances T cell responses (46) and is important for cancer immunosurveillance and the efficacy of cancer immunotherapies (38, 52, 53).”
BackgroundImmune Infiltration in Human Cancer: Prognostic Significance and Disease Control
Fridman, W. H., Galon, J., Dieu-Nosjean, M.-C., Cremer, I., Fisson, S., Damotte, D., Pagès, F., Tartour, E., & Sautès-Fridman, C. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_46 · Cited by 258
“These observations are reminiscent of the findings of Schreiber and Smyth (Koebel et al. 2007; Dunn et al. 2006; Smyth et al. 2006) demonstrating in mice that the equilibrium phase was largely dependent on IFNg.”
ResultAntitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 253
Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 252
Labidi-Galy, S. I., Sisirak, V., Meeus, P., Gobert, M., Treilleux, I., Bajard, A., Combes, J.-D., Faget, J., Mithieux, F., Cassignol, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0367 · Cited by 239
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 255
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
“It should be noted however, that these cells, termed T C 2 (as opposed to T C 1 CD8 + T cells activated in the presence of IL-12), were still able to improve survival from B16 melanoma cells in the lung when transferred in greater quantities (95).”
InfluentialImmune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
Dai, X., Bu, X., Gao, Y., Guo, J., Hu, J., Jiang, C., Zhang, Z., Xu, K., Duan, J., He, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.037 · Cited by 242
Ohkuri, T., Ghosh, A., Kosaka, A., Zhu, J., Ikeura, M., David, M., Watkins, S. C., Sarkar, S. N., & Okada, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0099 · Cited by 252
“Although a growing body of evidence suggests that endogenously produced type I IFNs participate in antitumor immune responses at the level of host hematopoietic cells (5, 6), the molecular mechanisms responsible for inducing the type I IFN in the sterile tumor microenvironment remain elusive.”
BackgroundAdams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
The danger theory: 20 years later
Pradeu, T., & Cooper, E. L. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00287 · Cited by 249
“Numerous recent data show that this view is inadequate (e.g., Dunn et al., 2006): the immune system does respond to tumors and eliminates many.”
BackgroundMacrophages as mediators of tumor immunosurveillance
Jaiswal, S., Chao, M. P., Majeti, R., & Weissman, I. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.001 · Cited by 246
Schreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H. J. G., Duiveman-de Boer, T., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., Pots, J. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2205 · Cited by 241
Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
Regis, G., Pensa, S., Boselli, D., Novelli, F., & Poli, V. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.06.004 · Cited by 236
Combinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 240
Engineering universal cells that evade immune detection
Lanza, R., Russell, D. W., & Nagy, A. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0200-1 · Cited by 230
Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., Ji, T., Zhang, H., Dong, W., Jin, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15207 · Cited by 212
“…increased levels of IFN-g are used to explain a good outcome by upregulating the MHC class I of tumour cells, targeting endothelium and inhibiting neoangiogenesis, activating M1 macrophages and NK cells, enhancing antitumour Th1 immune response, and directly inducing tumour cell apoptosis 51 .”
RetractedLiu, Y., Liu, X., Zhang, N., Yin, M., Dong, J., Zeng, Q., Mao, G., Song, D., Liu, L., & Deng, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.014 · Cited by 237
Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., Kitamura, H., & Nishimura, T. (2010) · European Journal of Immunology · doi:10.1002/eji.200940157 · Cited by 236
Görgün, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M., Cirstea, D., Santo, L., Hu, Y., Tai, Y.-T., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279893 · Cited by 230
“2 As in other cancers, the immune system can modulate MM cell growth: tumor development can promote immunosuppression; and conversely, immunosuppression may support tumor development.(3-6) Novel biological agents targeting not only tumor cells but also tumor cell-host interactions, cytokines, and the BM microenvironme…”
BackgroundTumor immunosurveillance in human cancers
Mlecnik, B., Bindea, G., Pagès, F., & Galon, J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9270-7 · Cited by 223
“At the molecular level, cancer progression is strongly influenced by this immunological pressure (cancer immunoediting) [35, 39].”
BackgroundSystemic vaccination induces CD8+ T cells and remodels the tumor microenvironment
Baharom, F., Ramirez-Valdez, R. A., Khalilnezhad, A., Khalilnezhad, S., Dillon, M., Hermans, D., Fussell, S., Tobin, K. K. S., Dutertre, C.-A., Lynn, G. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.10.006 · Cited by 219
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Hazini, A., Fisher, K., & Seymour, L. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002899 · Cited by 203
Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 221
“1947" language="eng" relation="no"> The immune system can protect against the formation of cancer in healthy individuals, but tumors develop spontaneously despite this surveillanc”
BackgroundChen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813175106 · Cited by 218
“Both prostate cancer and nonmalignant tissues had higher mRNA levels for IFN- , a Th1 cytokine (26), and T-bet, a transcription factor responsible for regulating IFN- production (27), as compared to untreated tissues.”
BackgroundMPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
Hasselbalch, H. C., & Bjørn, M. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/102476 · Cited by 206
“During this evolution from early cancer stage to the metastatic stage with MF, the interferons are important cytokines for immunity and cancer immunoediting [95].”
BackgroundCytokine-Induced Modulation of Colorectal Cancer
Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00096 · Cited by 216
Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression
Yanai, H., Chen, H.-M., Inuzuka, T., Kondo, S., Mak, T. W., Takaoka, A., Honda, K., & Taniguchi, T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611559104 · Cited by 216
Mayer-Barber, K. D., & Yan, B. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.25 · Cited by 213
Ho, S. S. W., Zhang, W. Y. L., Tan, N. Y. J., Khatoo, M., Suter, M. A., Tripathi, S., Cheung, F. S. G., Lim, W. K., Tan, P. H., Ngeow, J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.010 · Cited by 207
“Type I IFNs were also shown to be critical in the rejection of prostate cancer and other cancers (Dunn et al., 2006), but the signals that induce the production of type I IFNs have not been defined in the context of cancer.”
BackgroundWenzel, J., & Tüting, T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.96 · Cited by 203
Khodarev, N. N., Roizman, B., & Weichselbaum, R. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3225 · Cited by 203
Immune responses to malignancies
Whiteside, T. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.045 · Cited by 204
“The presence of antitumor cellular responses, humoral responses, or both to tumor-associated antigens (TAs) has been observed in many, but not all, patients with cancer.(1,2) The evidence for such pre-existing antitumor immunity in patients with cancer confirms that the tumor-bearing host is capable of mounting an imm…”
BackgroundSTAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas
Chan, S. R., Vermi, W., Luo, J., Lucini, L., Rickert, C., Fowler, A. M., Lonardi, S., Arthur, C., Young, L. J., Levy, D. E., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3100 · Cited by 193
“The latter finding shows that STAT1 is important in manifesting the IFN-dependent, cell-extrinsic tumor suppressor actions of immunity (that is, the elimination phase of cancer immunoediting [14]).”
BackgroundSelf-citationDying cell clearance and its impact on the outcome of tumor radiotherapy
Lauber, K., Ernst, A., Orth, M., Herrmann, M., & Belka, C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00116 · Cited by 187
“…predominantly affects macrophages, DCs, and NK cells leading to their activation and/or maturation, the upregulation of chemokine expression, the enhancement of antigen-presentation and crosspresentation by DCs and a robustly augmented induction of adaptive immune responses (Dunn et al., 2006).”
BackgroundInfluentialImmune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Brahmer, J. R., & Pardoll, D. M. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0078 · Cited by 190
“nogenic neoepitopes (7) or through the induction of antigenspecific tolerance (8, 9).”
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice
Mundy-Bosse, B. L., Lesinski, G. B., Jaime-Ramirez, A. C., Benninger, K., Khan, M., Kuppusamy, P., Guenterberg, K., Kondadasula, S. V., Chaudhury, A. R., La Perle, K. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189
“Type I and II IFNs play a critical role in mediating the response to immune-based therapies (24).”
BackgroundImmunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 182
“The ability of the immune system to eliminate nascent transformed cells, control and sculpt the immunogenicity of developing tumors while in a state of equilibrium, and upon escape of the immune control, exert pro-tumor functions, are all contemplated in the cancer immunoediting hypothesis [7, 8].”
BackgroundGenome-Derived Cytosolic DNA Mediates Type I Interferon-Dependent Rejection of B Cell Lymphoma Cells
Shen, Y. J., Le Bert, N., Chitre, A. A., Koo, C. X., Nga, X. H., Ho, S. S. W., Khatoo, M., Tan, N. Y., Ishii, K. J., & Gasser, S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.041 · Cited by 184
How tumours escape mass destruction
Stewart, T. J., & Abrams, S. I. (2008) · Oncogene · doi:10.1038/onc.2008.268 · Cited by 185
“In mouse models, it was demonstrated that the loss of immune function, especially affecting interferon-g (IFN-g) production, T lymphocytes and natural killer cells or their effector mechanisms, resulted in a significantly elevated incidence and rate of spontaneous, chemically induced or autochthonous tumour formation…”
BackgroundInfluentialT-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses
Zhu, Y., Ju, S., Chen, E., Dai, S., Li, C., Morel, P., Liu, L., Zhang, X., & Lu, B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000749 · Cited by 189
Benevides, L., da Fonseca, D. M., Donate, P. B., Tiezzi, D. G., De Carvalho, D. D., de Andrade, J. M., Martins, G. A., & Silva, J. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0054 · Cited by 182
“Although it was suggested that IFNg plays a role in the regulation of antitumor immune responses (26), our results indicate that IFNg does not play a direct role in controlling tumor development in the 4T1 model.”
ResultThe Interferon Stimulated Gene 54 Promotes Apoptosis
Stawowczyk, M., Van Scoy, S., Kumar, K. P., & Reich, N. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.207068 · Cited by 186
The untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
Mechanism of Action of Immunotherapy
Disis, M. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.004 · Cited by 175
Yoshihara, K., Tsunoda, T., Shigemizu, D., Fujiwara, H., Hatae, M., Fujiwara, H., Masuzaki, H., Katabuchi, H., Kawakami, Y., Okamoto, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2725 · Cited by 189
“IFN-γ or other cytokines stimulation induces the expression of genes in the antigen presentation pathway (38).”
BackgroundA mathematical model of tumor–immune interactions
Robertson-Tessi, M., El-Kareh, A., & Goriely, A. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.10.027 · Cited by 187
“Furthermore, immunodeficient mice have been shown to have increased incidence of cancers (Dunn et al., 2006), and human patients taking immunosuppressive agents also show increased susceptibility to many cancer types (Wimmer et al., 2007), suggesting that the immune system plays a role in the…”
BackgroundIFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Alizadeh, D., Wong, R. A., Gholamin, S., Maker, M., Aftabizadeh, M., Yang, X., Pecoraro, J. R., Jeppson, J. D., Wang, D., Aguilar, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1661 · Cited by 170
“IFN γ is also involved in recruitment and activation of cytotoxic T cells, polarization of CD4 + T cells into Th1 effector cells, and reduction of tumor-promoting Treg development and function (16–18).”
Lévy, J., Cacheux, W., Bara, M. A., L’Hermitte, A., Lepage, P., Fraudeau, M., Trentesaux, C., Lemarchand, J., Durand, A., Crain, A.-M., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3206 · Cited by 189
Trafficking properties of plasmacytoid dendritic cells in health and disease
Sozzani, S., Vermi, W., Del Prete, A., & Facchetti, F. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.05.004 · Cited by 171
Mejías, R., Pérez-Yagüe, S., Gutiérrez, L., Cabrera, L. I., Spada, R., Acedo, P., Serna, C. J., Lázaro, F. J., Villanueva, Á., Morales, M. D. P., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.008 · Cited by 186
“IFN-g is a prototypic cytokine with anti-tumor activity that can potentiate the immune response to tumors [70]; it promotes activation and infiltration of CD8þ cytotoxic T lymphocytes, natural killer cells and macrophages into tumor tissue, increases tumor cell immunogenicity and apoptosis, and inhibits tumor angiogen…”
De Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
“Subsets of these cells, such as CD8þ cytotoxic Tcells and natural killer (NK) cells, may play roles in restricting tumor development and progressive growth (de Visser et al., 2006; Dunn et al., 2006).”
BackgroundCurrent concepts in clinical radiation oncology
Orth, M., Lauber, K., Niyazi, M., Friedl, A. A., Li, M., Maihöfer, C., Schüttrumpf, L., Ernst, A., Niemöller, O. M., & Belka, C. (2014) · Radiation and Environmental Biophysics · doi:10.1007/s00411-013-0497-2 · Cited by 178
“…macrophages, DCs, and NK cells by facilitating their activation and maturation and by enhancing their capacity to induce adaptive immune responses (Dunn et al. 2006), IFN-c directly affects the tumor via inhibition of tumor cell proliferation, apoptosis induction, inhibition of angiogenesis, and…”
BackgroundInfluentialNguyên, T. L.-A., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.-S., Yasmeen, A., Bismar, T. A., Kirn, D., Falls, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803988105 · Cited by 182
“As an example, tumors often develop a diminished response to the antiviral IFN cytokines, perhaps because of strong selective pressure to avoid immune surveillance (6).”
BackgroundCXCR2‐mediated tumor‐associated neutrophil recruitment is regulated by IFN‐β
Jablonska, J., Wu, C. ‐., Andzinski, L., Leschner, S., & Weiss, S. (2014) · International Journal of Cancer · doi:10.1002/ijc.28551 · Cited by 179
IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment
Nirschl, C. J., Suárez-Fariñas, M., Izar, B., Prakadan, S., Dannenfelser, R., Tirosh, I., Liu, Y., Zhu, Q., Devi, K. S. P., Carroll, S. L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.016 · Cited by 182
Bioengineered nanogels for cancer immunotherapy
Ma, X., Li, S.-J., Liu, Y., Zhang, T., Xue, P., Kang, Y., Sun, Z.-J., & Xu, Z. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00247g · Cited by 185
Budhwani, M., Mazzieri, R., & Dolcetti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00322 · Cited by 181
“Interferons (IFNs) comprise a large family of cytokines that have been studied extensively in the context of virus infections but they are now also known as key drivers of inflammation within the tumor microenvironment (3).”
BackgroundSurace, L., Lysenko, V., Fontana, A. O., Cecconi, V., Janssen, H., Bicvic, A., Okoniewski, M., Pruschy, M., Dummer, R., Neefjes, J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.009 · Cited by 179
“…there is a positive correlation between tumor infiltration by effector T cells and survival (Fridman et al., 2011), and the risk to develop cancer is increased in immunosuppressed patients (Dunn et al., 2006), and dormant tumors are kept in check by the adaptive immune system (Koebel et al., 2007).”
BackgroundCamicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 169
“Initially, IFNγ/STAT1 signaling helps protecting the host from tumor formation and development (immune surveillance), but subsequently IFNγ can also promote the tumors to resist attack (immunoediting) and escape by Darwinian evolution [473, 497, 526].”
BackgroundInfluentialType I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response
Schiavoni, G., Mattei, F., & Gabriele, L. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00483 · Cited by 169
“In addition, IFN-I has been shown to be a crucial component of cancer-immunoediting, namely the process whereby the immune system suppresses cancer growth and shapes tumor immunogenicity (76,77).”
BackgroundRole of T lymphocytes in tumor response to radiotherapy
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00095 · Cited by 174
“Keywords: abscopal, adjuvant, CD8 T cells, dendritic cells, immunoediting, immunotherapy, ionizing radiation, in situ vaccine”
BackgroundThe RAG Recombinase Dictates Functional Heterogeneity and Cellular Fitness in Natural Killer Cells
Karo, J. M., Schatz, D. G., & Sun, J. C. (2014) · Cell · doi:10.1016/j.cell.2014.08.026 · Cited by 169
“of CTL maturation, and various affects on tumor cells (Dunn et al., 2006).”
Human interferon-λ3 is a potent member of the type III interferon family
Dellgren, C., Gad, H. H., Hamming, O. J., Melchjorsen, J., & Hartmann, R. (2009) · Genes & Immunity · doi:10.1038/gene.2008.87 · Cited by 170
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy
Schaafsma, E., Fugle, C. M., Wang, X., & Cheng, C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01400-2 · Cited by 167
T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy
Zhai, Y., Wang, J., Lang, T., Kong, Y., Rong, R., Cai, Y., Ran, W., Xiong, F., Zheng, C., Wang, Y., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00972-7 · Cited by 170
SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis
Yoo, J.-S., Sasaki, M., Cho, S. X., Kasuga, Y., Zhu, B., Ouda, R., Orba, Y., de Figueiredo, P., Sawa, H., & Kobayashi, K. S. (2021) · Nature Communications · doi:10.1038/s41467-021-26910-8 · Cited by 166
BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response
Yan, Q., Dutt, S., Xu, R., Graves, K., Juszczynski, P., Manis, J. P., & Shipp, M. A. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.019 · Cited by 164
“Previous studies highlight the dual role of g-IFN in tumor immunity, initially protecting the host from the tumor formation but subsequently ‘‘immunoediting’’ established tumors to resist attack (Bui and Screiber, 2007; Dunn et al., 2006).”
Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
Zeestraten, E. C. M., Reimers, M. S., Saadatmand, S., Dekker, J.-W. T., Liefers, G. J., van den Elsen, P. J., van de Velde, C. J. H., & Kuppen, P. J. K. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.696 · Cited by 165
de la Luz Garcia-Hernandez, M., Gray, A., Hubby, B., Klinger, O. J., & Kast, W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0445 · Cited by 169
“This process is consistent with the tumor immunoediting paradigm proposed by Dunn et al. ( 42 ).”
ResultLiang, H., Deng, L., Chmura, S., Burnette, B., Liadis, N., Darga, T., Beckett, M. A., Lingen, M. W., Witt, M., Weichselbaum, R. R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202612 · Cited by 165
Thibaut, R., Bost, P., Milo, I., Cazaux, M., Lemaître, F., Garcia, Z., Amit, I., Breart, B., Cornuot, C., Schwikowski, B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0038-2 · Cited by 160
Zhang, C., Peng, L., Zhang, Y., Liu, Z., Li, W., Chen, S., & Li, G. (2017) · Medical Oncology · doi:10.1007/s12032-017-0963-9 · Cited by 165
“Type I interferon, including IFN-a and IFN-b, can directly inhibit the proliferation and facilitate the apoptosis of tumor cell, or indirectly regulate tumor microenvironment [17, 18].”
BackgroundKim, I.-K., Kim, B.-S., Koh, C.-H., Seok, J.-W., Park, J.-S., Shin, K.-S., Bae, E.-A., Lee, G.-E., Jeon, H., Cho, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3922 · Cited by 167
The Role of Structure in the Biology of Interferon Signaling
Walter, M. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606489 · Cited by 186
Park, A., Lee, Y., Kim, M. S., Kang, Y. J., Park, Y.-J., Jung, H., Kim, T.-D., Lee, H. G., Choi, I., & Yoon, S. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01859 · Cited by 163
“Cancer Immunol Immunother (2011) 60(11):1577–86.”
Brichard, V. G., & Lejeune, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.038 · Cited by 160
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 182
“Furthermore, the tumor stroma, in particular endothelial cells, and the tumor microenvironment play a key role in this process [ 14 , 60].”
BackgroundStructural basis of recognition of interferon-α receptor by tyrosine kinase 2
Wallweber, H. J. A., Tam, C., Franke, Y., Starovasnik, M. A., & Lupardus, P. J. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2807 · Cited by 165
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.